Alvogen Group (PRIVATE.ALVOGEN)

Overall impact
C (52)

Commentary

Alvogen Group is an average overall performer. With a 'C' rating of 52.0 for overall impact (45th percentile compared to all companies), Alvogen Group ranks 133rd out of 157 industry peers, behind DiaMedica Therapeutics, HOOKIPA Pharma, Centrient Pharmaceuticals and 129 others, and ahead of Sun Pharmaceutical Industries, Talphera, Endo International and 21 others. On top material causes for Alvogen Group's industry (Pharmaceuticals & Biotech), Alvogen Group performs well in Technology Innovation (94.7 score), Access to Affordable Healthcare (81.0), Disease Eradication (96.1) and 1 other cause where it received an 'A' score and performs poorly in Reduced Inequality (24.9 score), Decent, Safe Work Opportunities (29.7), Sustainable Use of Natural Resources (29.5) and 6 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.ALVOGEN
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2007
Employees
2,800
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
New Jersey, United States
Share classes
PRIVATE.ALVOGEN
Description
Manufacturer of specialty pharmaceutical generic and branded products dedicated to helping people live long healthy and active lives. The company offers a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology. This ensures affordable generic medications that help reduce healthcare costs around the world.
Material causes
Ethos considers the following causes material for Alvogen Group, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.